FDG PET‐CT in pediatric Langerhans cell histiocytosis
| العنوان: | FDG PET‐CT in pediatric Langerhans cell histiocytosis |
|---|---|
| المؤلفون: | Sophie R Jessop, Donna Crudgington, Stewart J. Kellie, Kevin London, Robert Howman-Giles |
| المصدر: | Pediatric Blood & Cancer. 67 |
| بيانات النشر: | Wiley, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Adolescent, 03 medical and health sciences, 0302 clinical medicine, Langerhans cell histiocytosis, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Biopsy, medicine, Humans, Stage (cooking), Child, Retrospective Studies, PET-CT, medicine.diagnostic_test, business.industry, Infant, Newborn, Infant, Magnetic resonance imaging, Hematology, Prognosis, medicine.disease, Combined Modality Therapy, Histiocytosis, Langerhans-Cell, Histiocytosis, Oncology, Positron emission tomography, Child, Preschool, 030220 oncology & carcinogenesis, Pediatrics, Perinatology and Child Health, Female, Radiology, Neoplasm Recurrence, Local, Radiopharmaceuticals, business, Progressive disease, Follow-Up Studies, 030215 immunology |
| الوصف: | Objective Langerhans cell histiocytosis (LCH) in pediatric patients presents with single-system or multisystem disease. Accurate staging is essential for selecting the most appropriate therapy ranging from local surgery to chemotherapy. Methods A retrospective review was undertaken of reported fludeoxyglucose (FDG) positron emission tomography - computed tomography (PET-CT) scans performed in children with LCH from June 2006 to February 2017. Findings were compared with a reference standard of biopsy or informed clinical follow-up. Results One hundred nine scans were performed in 33 patients (age 7 weeks to 18 years). Nineteen patients had single-system, bone unifocal disease; seven patients had single-system, bone multifocal disease; four patients had single-system, skin unifocal disease; two patients had multisystem disease; and one patient had single-system, lymph node disease. Twenty-six scans were performed to stage biopsy-proven LCH, and 83 scans were performed during follow-up to assess treatment response or recurrence after therapy completion. At staging, FDG PET-CT detected all sites of biopsy-proven LCH (except where bone unifocal disease had been resected). There was one false-positive thymic finding that resolved without therapy. The per-patient false-positive rate of FDG PET-CT at staging was 4% (1/26). During follow-up, five LCH recurrences and one case of progressive disease on therapy occurred, all positive on FDG PET-CT. During follow-up two patients had FDG PET-CT scans with false-positive findings and one patient with a magnetic resonance imaging false-positive finding. The per-scan false-positive rate of FDG PET-CT during follow-up was 2% (2/83). Conclusions FDG PET-CT is highly sensitive for the staging and follow-up of pediatric patients with LCH, and has a very low false-positive rate. |
| تدمد: | 1545-5017 1545-5009 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac1ce46495d58270e9e9aac6cfa9567b https://doi.org/10.1002/pbc.28034 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....ac1ce46495d58270e9e9aac6cfa9567b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15455017 15455009 |
|---|